Kooperativer Bibliotheksverbund

Berlin Brandenburg

and
and

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Language: English
    In: Biomaterials, 03/2010, Vol.31(8), pp.2388-2398
    Description: To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.biomaterials.2009.11.093 Byline: Sylvia Wagner (a), Florian Rothweiler (b), Marion G. Anhorn (c), Daniel Sauer (a), Iris Riemann (a), Eike C. Weiss (a), Alisa Katsen-Globa (a), Martin Michaelis (b), Jindrich Cinatl (b), Daniel Schwartz (d), Jorg Kreuter (c), Hagen von Briesen (a), Klaus Langer (e) Abstract: Specific transport of anti-cancer drugs into tumor cells may result in increased therapeutic efficacy and decreased adverse events. Expression of [alpha]v[beta]3 integrin is enhanced in various types of cancer and monoclonal antibodies (mAbs) directed against [alpha]v[beta]3 integrins hold promise for anti-cancer therapy. DI17E6 is a monoclonal antibody directed against [alpha]v integrins that inhibits growth of melanomas in vitro and in vivo and inhibits angiogenesis due to interference with [alpha]v[beta]3 integrins. Here, DI17E6 was covalently coupled to human serum albumin nanoparticles. Resulting nanoparticles specifically targeted [alpha]v[beta]3 integrin positive melanoma cells. Moreover, doxorubicin loaded DI17E6 nanoparticles showed increased cytotoxic activity in [alpha]v[beta]3-positive melanoma cells than the free drug. Therefore, DI17E6-coupled human serum albumin nanoparticles represent a potential delivery system for targeted drug transport into [alpha]v[beta]3-positive cells. Author Affiliation: (a) Fraunhofer Institute for Biomedical Engineering, D-66386 St.Ingbert, Germany (b) Institut fur Medizinische Virologie, Universitatsklinikum, Goethe-University, D-60590 Frankfurt, Germany (c) Institute of Pharmaceutical Technology, Biocenter of Goethe-University, D-60438 Frankfurt, Germany (d) Merck Serono, Biotech Products Development, D-64293 Darmstadt, Germany (e) Institute of Pharmaceutical Technology and Biopharmacy, Westfalische Wilhelms Universitat, Corrensstrasse 1, D-48149 Munster, Germany Article History: Received 4 November 2009; Accepted 26 November 2009
    Keywords: Drugs ; Monoclonal Antibodies ; Serum Albumin ; Anthracyclines ; Biological Products ; Integrins ; Melanoma ; Nanoparticles;
    ISSN: 01429612
    E-ISSN: 18785905
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Language: English
    In: International journal of pharmaceutics, 2011, Vol.415(1), pp.244-251
    Description: Glioblastomas belong to the most devastating cancer diseases. For this reason, polysorbate 80 (Tween 80®)-coated poly(isohexyl cyanoacrylate) (PIHCA) (Monorex®) nanoparticles loaded with doxorubicin were developed and tested for their use for the treatment of glioblastomas. The preparation of the nanoparticles resulted in spherical particles with high doxorubicin loading. The physico-chemical properties and the release of doxorubicin from the PIHCA-nanoparticles were analysed, and the influence on cell viability of the rat glioblastoma 101/8-cell line was investigated. In vitro, the empty nanoparticles did not show any toxicity, and the anti-cancer effects of the drug-loaded nanoparticles were increased in comparison to doxorubicin solution, represented by IC₅₀ values. The in vivo efficacy was then tested in intracranially glioblastoma 101/8-bearing rats. Rats were treated with 3×1.5mg/kg doxorubicin and were sacrificed 18 days after tumour transplantation. Histological and immunohistochemical analyses were carried out to assess the efficacy of the nanoparticles. Tumour size, proliferation activity, vessel density, necrotic areas, and expression of glial fibrillary acidic protein demonstrated that doxorubicin-loaded PIHCA-nanoparticles were much more efficient than the free drug. The results suggest that poly(isohexyl cyanoacrylate) nanoparticles hold great promise for the non-invasive therapy of human glioblastomas. ; p. 244-251.
    Keywords: Therapeutics ; Doxorubicin ; Toxicity ; Cell Viability ; Immunohistochemistry ; Polysorbates ; Physicochemical Properties ; Neoplasms ; Inhibitory Concentration 50 ; Humans ; Rats ; Nanoparticles
    ISSN: 0378-5173
    E-ISSN: 18733476
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Language: English
    In: Molecular Cancer, 2009, Vol.8(1), pp.urn:issn:1476-4598
    Description: Background: Chemoresistance acquisition may influence cancer cell biology. Here, bioinformatics analysis of gene expression data was used to identify chemoresistance-associated changes in neuroblastoma biology. Results: Bioinformatics analysis of gene expression data revealed that expression of angiogenesis-associated...
    Keywords: Endothelial Growth-Factor ; In-Vivo ; Melanoma-Cells ; Tumor-Growth ; N-Myc ; Extracellular-Matrix ; Angiogenic Factors ; Cytokine Network ; Vegf Expression ; Blood-Vessels
    ISSN: 1476-4598
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Language: English
    In: Beilstein Journal of Nanotechnology, 01 August 2019, Vol.10(1), pp.1707-1715
    Description: Resistance to systemic drug therapy is a major reason for the failure of anticancer therapies. Here, we tested doxorubicin-loaded human serum albumin (HSA) nanoparticles in the neuroblastoma cell line UKF-NB-3 and its ABCB1-expressing sublines adapted to vincristine (UKF-NB-3rVCR1) and doxorubicin...
    Keywords: Abcb1 ; Cancer ; Doxorubicin ; Drug Resistance ; Human Serum Albumin ; Nanoparticles ; Transporter ; Engineering
    ISSN: 2190-4286
    E-ISSN: 2190-4286
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages